Kevan Anderson
About
In The Last Decade
Kevan Anderson
27 papers receiving 807 citations
Peers
Comparison fields: 5 of 95
- Neurology 383
- Radiology, Nuclear Medicine and Imaging 302
- Biomedical Engineering 121
- Cellular and Molecular Neuroscience 114
- Surgery 110
Countries citing papers authored by Kevan Anderson
This map shows the geographic impact of Kevan Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevan Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevan Anderson more than expected).
Fields of papers citing papers by Kevan Anderson
This network shows the impact of papers produced by Kevan Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevan Anderson. The network helps show where Kevan Anderson may publish in the future.
Co-authorship network of co-authors of Kevan Anderson
This figure shows the co-authorship network connecting the top 25 collaborators of Kevan Anderson. A scholar is included among the top collaborators of Kevan Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevan Anderson. Kevan Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 49 | |
| 3 | 27 | |
| 4 | 49 | |
| 5 | 8 | |
| 6 | 4 | |
| 7 | 49 | |
| 8 | A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition - eScholarship | 0 |
| 9 | 6 | |
| 10 | 20 | |
| 11 | Retrospective analysis of the long term safety of lenalidomide (Len)±dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM) | 4 |
| 12 | 2 | |
| 13 | 38 | |
| 14 | 6 | |
| 15 | 26 | |
| 16 | 42 | |
| 17 | 19 | |
| 18 | 25 | |
| 19 | 4 | |
| 20 | 37 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.